Thymic carcinomas are rare tumors of the thymus arising in the thymic epithelium.They represent less than 1%of thymic malignancies.They often present with an advanced disease and metastasize to regional lymph nodes and distant sites.They have a worse prognosis with a 5-year survival rate of 30%-50%,while thymomas are much less invasive and have a 5-year survival of approximately 78%.We report a rare form of clinical presentation of a thymic carcinoma in which the diagnosis of myasthenia gravis was the cornerstone of the diagnosis of cancer.Surgery is considered the salvage treatment when possible.Radiotherapy is a second choice of salvage treatment,when possible depending on its localization and relation to nearby structures such as vascular structures.Molecular target therapy is a more directed,more expensive but less toxic treatment.Further studies need to be carried out for its approval worldwide,outside clinical trials.